Tiziana Lifesciences Develops Novel Investigational Treatment For Patients Infected with COVID-19 Utilizing Direct Delivery of Anti-Interlukin-6-Receptor Monoclonal Antibodies

Stock Information for Tiziana Life Sciences plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tiziana Life Sciences plc

Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 million
Tiziana Life Sciences plc: Early notification of proposed admission to the Official List and cancellation of trading on AIM
Tiziana Life Sciences to Participate in Investor Webinar to Provide Corporate Updates and Q&A Session on July 30, 2020
Tiziana Life Sciences plc ("Tiziana" or the "Company") Director Appointment
Tiziana Life Sciences plc Change to ADS Ratio - Updated
Tiziana Life Sciences plc Change to ADS Ratio
Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report
Tiziana Life Sciences Announces Agreement with STC Biologics for GMP Manufacturing of an anti-Interleukin-6-Receptor Monoclonal Antibody for Clinical Studies in Patients with COVID-19

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.